Skip to main content
SpringerLink
Log in

Management of mucous membrane pemphigoid: a literature review and update

  • Review
  • Published:
European Journal of Dermatology

Abstract

Mucous membrane pemphigoid (MMP) is a rare group of heterogeneous chronic autoimmune diseases that predominantly manifest as blistering of the mucous membranes. MMP lesions often heal with scarring, which may result in impaired organ function and significant morbidity. The exact pathogenic mechanisms of MMP are still largely unknown while the diagnosis is based on a combination of clinical, histological and immuno-pathological findings. Several treatment modalities of MMP are available and are reported in the literature, however, such treatment options are principally guided by expert opinions and descriptive reports. Non-specific immunosuppression, especially corticosteroids, remains the mainstay of treatment, which often leads to severe adverse effects. Therefore, safer and more effective therapeutic modalities are required. This comprehensive literature review outlines the current knowledge and recent advances in the field of MMP management, with particular emphasis on the oral variant of MMP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 2002; 138: 370–9.

    Article  PubMed  Google Scholar 

  2. Di Zenzo G, Carrozzo M, Chan LS. Urban legend series: mucous membrane pemphigoid. Oral Dis 2014; 20: 35–54.

    Article  CAS  PubMed  Google Scholar 

  3. Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145: 778–83.

    Article  CAS  PubMed  Google Scholar 

  4. Benoit S, Schmidt E, Sitaru C, et al. Anti-laminin 5 mucous membrane pemphigoid. J Dtsch Dermatol Ges 2006; 4: 41–4.

    Article  PubMed  Google Scholar 

  5. Hayakawa T, Furumura M, Fukano H, et al. Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: 483–96.

    Article  PubMed  Google Scholar 

  6. Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 43440.

    Article  Google Scholar 

  7. Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001; 145: 406–14.

    Article  CAS  PubMed  Google Scholar 

  8. Hubner F, Setterfield J, Recke A, et al. HLA alleles in British Caucasians with mucous membrane pemphigoid. Eye (Lond) 2018; 32: 1540–1.

    Article  CAS  Google Scholar 

  9. Sadik CD, Bischof J, van Beek N, et al. Genomewide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid. Exp Dermatol 2017; 26: 1214–20.

    Article  CAS  PubMed  Google Scholar 

  10. Leuci S, Ruoppo E, Adamo D, Calabria E, Mignogna MD. Oral autoimmune vesicobullous diseases: classification, clinical presentations, molecular mechanisms, diagnostic algorithms and management. Periodontol 2019; 80: 77–88.

    Article  Google Scholar 

  11. Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita — Brazilian Society of Dermatology. An Bras Dermatol 2019; 94: 33–47.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Taylor J, McMillan R, Shephard M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 161–71 e20.

    Article  CAS  PubMed  Google Scholar 

  13. Arduino PG, Farci V, D’Aiuto F, et al. Periodontal status in oral mucous membrane pemphigoid: initial results of a case-control study. Oral Dis 2011; 17: 904.

    Article  Google Scholar 

  14. van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges 2018; 16: 1077–91.

    PubMed  Google Scholar 

  15. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320–32.

    Article  PubMed  Google Scholar 

  16. Meijer JM, Diercks GF, Schmidt E, Pas HH, Jonkman MF. Laboratory diagnosis and clinical profile of Anti-p200 Pemphigoid. JAMA Dermatol 2016; 152: 897–904.

    Article  PubMed  Google Scholar 

  17. Solimani F, Pollmann R, Ishii N, et al. Diagnosis of anti-laminin gamma-1 pemphigoid by immunoblot analysis. J Eur Acad Dermatol Venereol 2019; 33: 735–41.

    Article  CAS  PubMed  Google Scholar 

  18. Solimani F, Maglie R, Pollmann R, et al. Thymoma-associated paraneoplastic autoimmune multiorgan syndrome-from pemphigus to lichenoid dermatitis. Front Immunol 2019; 10: 1413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Giurdanella F, Nijenhuis AM, Diercks GFH, Jonkman MF, Pas HH. Keratinocyte footprint assay discriminates antilaminin-332 pemphigoid from all other forms of pemphigoid diseases. Br J Dermatol 2020; 182: 373–81.

    Article  CAS  PubMed  Google Scholar 

  20. Frank DE, Carter WG. Laminin 5 deposition regulates keratinocyte polarization and persistent migration. J Cell Sci 2004; 117: 1351–63.

    Article  CAS  PubMed  Google Scholar 

  21. van Beek N, Rentzsch K, Probst C, et al. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012; 7: 49.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ali S, Kelly C, Challacombe SJ, et al. Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid. Br J Dermatol 2016; 174: 1022–9.

    Article  CAS  PubMed  Google Scholar 

  23. Murrell DF, Marinovic B, Caux F, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 2015; 72: 168–74.

    Article  PubMed  Google Scholar 

  24. Buonavoglia A, Leone P, Dammacco R, et al. Pemphigus and mucous membrane pemphigoid: an update from diagnosis to therapy. Autoimmun Rev 2019; 18: 349–58.

    Article  PubMed  Google Scholar 

  25. Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010; 23: 268–80.

    Article  PubMed  Google Scholar 

  26. Kourosh AS, Yancey KB. Therapeutic approaches to patients with mucous membrane pemphigoid. Dermatol Clin 2011; 29: 637–41.

    Article  CAS  PubMed  Google Scholar 

  27. Amber KT, Lamberts A, Solimani F, et al. Determining the incidence of pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis. JAMA Dermatol 2017; 153: 1137–41.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rogers RS, 3rd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7: 201–5.

    PubMed  Google Scholar 

  29. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998; 23: 254–7.

    Article  CAS  PubMed  Google Scholar 

  30. Carrozzo M, Arduino P, Bertolusso G, Cozzani E, Parodi A. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg 2009; 38: 1071–6.

    Article  CAS  PubMed  Google Scholar 

  31. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193–7.

    Article  CAS  PubMed  Google Scholar 

  32. Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol 1984; 11: 1115–26.

    Article  CAS  PubMed  Google Scholar 

  33. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139: 1051–9.

    Article  CAS  PubMed  Google Scholar 

  34. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106: 2136–43.

    Article  CAS  PubMed  Google Scholar 

  35. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002; 102: 59–67.

    Article  CAS  PubMed  Google Scholar 

  36. Bystryn JC, Rudolph JL. IVI g treatment of pemphigus: how it works and how to use it. J Invest Dermatol 2005; 125: 1093–8.

    Article  CAS  PubMed  Google Scholar 

  37. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80–6.

    Article  CAS  PubMed  Google Scholar 

  38. Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis and treatment. Autoimmunity 2012; 45: 55–70.

    Article  CAS  PubMed  Google Scholar 

  39. Lozada-Nur F, Huang MZ, Zhou GA. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1991; 71: 283–7.

    Article  CAS  PubMed  Google Scholar 

  40. Muzyka BC. Oral fungal infections. Dent Clin North Am 2005; 49: 49–65.

    Article  PubMed  Google Scholar 

  41. Assmann T, Homey B, Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother 2001; 2: 1167–75.

    Article  CAS  PubMed  Google Scholar 

  42. Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004; 29: 674–6.

    Article  CAS  PubMed  Google Scholar 

  43. Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol 2011; 91: 604–5.

    Article  CAS  PubMed  Google Scholar 

  44. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–32.

    CAS  PubMed  Google Scholar 

  45. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 602–3.

    Article  CAS  PubMed  Google Scholar 

  46. Amber KT, Maglie R, Solimani F, Eming R, Hertl M. Targeted therapies for autoimmune bullous diseases: current status. Drugs 2018; 78: 1527–48.

    Article  PubMed  Google Scholar 

  47. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545–52.

    Article  CAS  PubMed  Google Scholar 

  48. Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 2013; 68: 404–11.

    Article  CAS  PubMed  Google Scholar 

  49. Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol 2014; 28: 771–80.

    Article  CAS  PubMed  Google Scholar 

  50. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352–6.

    Article  CAS  PubMed  Google Scholar 

  51. Wittenberg M, Worm M. Severe refractory paraneoplastic mucous membrane pemphigoid successfully treated with rituximab. Front Med (Lausanne) 2019; 6: 8.

    Article  Google Scholar 

  52. Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horvath B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol 2018; 9: 248.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Bernauer W, Schuler S, Borradori L. Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid. J Ophthalmic Inflamm Infect 2018; 8: 12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hugel R, Lang A, Lhotta K, et al. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement — adjuvant treatment with immunoadsorption and rituximab. J Dtsch Dermatol Ges 2018; 16: 897–900.

    Article  PubMed  Google Scholar 

  55. Haefliger S, Horn MP, Suter VG, Bornstein MM, Borradori L. Rituximab for the treatment of isolated refractory desquamative gingivitis due to mucous membrane pemphigoid. JAMA Dermatol 2016; 152: 1396–8.

    Article  PubMed  Google Scholar 

  56. Steger B, Madhusudan S, Kaye SB, et al. Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis-an interventional case series. Cornea 2016; 35: 1611–4.

    Article  PubMed  Google Scholar 

  57. Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74: 835–40.

    Article  CAS  PubMed  Google Scholar 

  58. Rubsam A, Stefaniak R, Worm M, Pleyer U. Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther 2015; 15: 927–33.

    Article  PubMed  Google Scholar 

  59. He Y, Shimoda M, Ono Y, et al. Persistence of autoreactive IgA-secreting B cells despite multiple immunosuppressive medications including rituximab. JAMA Dermatol 2015; 151: 646–50.

    Article  PubMed  Google Scholar 

  60. Heelan K, Hassan S, Bannon G, et al. Cost and resource use of pemphigus and pemphigoid disorders pre- and post-rituximab. J Cutan Med Surg 2015; 19: 274–82.

    Article  PubMed  Google Scholar 

  61. Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2013; 68: 499–506.

    Article  CAS  PubMed  Google Scholar 

  62. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147: 843–9.

    Article  CAS  PubMed  Google Scholar 

  63. Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011; 25: 1238–40.

    Article  CAS  PubMed  Google Scholar 

  64. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552–8.

    Article  CAS  PubMed  Google Scholar 

  65. Schumann T, Schmidt E, Booken N, Goerdt S, Goebeler M. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2009; 89: 101–2.

    Article  PubMed  Google Scholar 

  66. Wollina U, Koch A, Hansel G. Rituximab therapy of recalcitrant bullous dermatoses. J Dermatol Case Rep 2008; 2: 4–7.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Milano A, Perri F, Caponigro F. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. Onco Targets Ther 2009; 2: 171–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Saeed L, Schmidt TH, Gensler LS, et al. Successful treatment of mucous membrane pemphigoid with bortezomib. JAAD Case Rep 2018; 4: 81–3.

    Article  PubMed  Google Scholar 

  69. Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib. JAMA Ophthalmol 2018; 136: 1420–2.

    Article  PubMed  Google Scholar 

  70. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006; 142: 1457–61.

    Article  CAS  PubMed  Google Scholar 

  71. Razzaque MS, Foster CS, Ahmed AR. Role of macrophage migration inhibitory factor in conjunctival pathology in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2004; 45: 1174–81.

    Article  PubMed  Google Scholar 

  72. Kasperkiewicz M, Platkowska A, Zalewska A, Zillikens D. Heat shock protein 90 inhibition: a potential double- or triple-edged sword in the treatment of mucous membrane pemphigoid. Med Hypotheses 2015; 85: 412–4.

    Article  CAS  PubMed  Google Scholar 

  73. Rice JW, Veal JM, Fadden RP, et al. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008; 58: 3765–75.

    Article  CAS  PubMed  Google Scholar 

  74. Heppe EN, Tofern S, Schulze FS, et al. Experimental Laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease. J Invest Dermatol 2017; 137: 1709–18.

    Article  CAS  PubMed  Google Scholar 

  75. Iwata H, Kamaguchi M, Ujiie H, et al. Fc-binding proteins enhance autoantibody-induced BP180 depletion in pemphigoid. J Pathol 2019; 247: 371–80.

    Article  CAS  PubMed  Google Scholar 

  76. Lo Russo L, Fedele S, Guiglia R, et al. Diagnostic pathways and clinical significance of desquamative gingivitis. J Periodontol 2008; 79: 4–24.

    Article  PubMed  Google Scholar 

  77. Lo Russo L, Guiglia R, Pizzo G, et al. Effect of desquamative gingivitis on periodontal status: a pilot study. Oral Dis 2010; 16: 102–7.

    Article  CAS  PubMed  Google Scholar 

  78. Schellinck AE, Rees TD, Plemons JM, Kessler HP, Rivera-Hidalgo F, Solomon ES. A comparison of the periodontal status in patients with mucous membrane pemphigoid: a 5-year follow-up. J Periodontol 2009; 80: 1765–73.

    Article  PubMed  Google Scholar 

  79. Tricamo MB, Rees TD, Hallmon WW, Wright JM, Cueva MA, Plemons JM. Periodontal status in patients with gingival mucous membrane pemphigoid. J Periodontol 2006; 77: 398–405.

    Article  PubMed  Google Scholar 

  80. Jascholt I, Lai O, Zillikens D, Kasperkiewicz M. Periodontitis in oral pemphigus and pemphigoid: a systematic review of published studies. J Am Acad Dermatol 2017; 76: 975–8 e3.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral and Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah Department of Oral Medicine and Oral Surgery, Faculty of Dentistry, Jordan University of Science and Technology, Ar-Ramtha, Jordan

    Mohammad S. Alrashdan

  2. Department of Oral Diagnosis and Medicine, Hokkaido University Graduate School of Dental Medicine, Hokkaido, Sapporo, Japan

    Mayumi Kamaguchi

Authors
  1. Mohammad S. Alrashdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mayumi Kamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad S. Alrashdan.

Additional information

Disclosures

Financial support: none. Conflicts of interest: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alrashdan, M.S., Kamaguchi, M. Management of mucous membrane pemphigoid: a literature review and update. Eur J Dermatol 32, 312–321 (2022). https://doi.org/10.1684/ejd.2021.4132

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2021.4132

Key words

Search

Navigation